InvestorWire NewsRoom


InvestorNewsBreaks – Pressure BioSciences Inc. (PBIO) Releases Q4 2022 Guidance, Projections for 2023
December 27, 2022

InvestorNewsBreaks – Pressure BioSciences Inc. (PBIO) Releases Q4 2022 Guidance, Projections for 2023

Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty process development and production services to the worldwide nutraceuticals, cosmetics, biotherapeutics and food/beverage industries, is sharing projections for its Q4 2022 revenue. According to the announcement, the company anticipates revenue for the last quarter of 2022 to “exceed quarterly revenue for any quarter over the past four years, and may achieve the highest quarterly revenue ever for the company.” PBIO attributed the growth to foundations built and momentum achieved earlier in 2022, which was driven by the commercial release of the company’s revolutionary Ultra Shear Technology(TM), or UST(TM) platform. “Our development of UltraShear over the past six years presented a pivotal, game-changing nanoemulsions technology that we believe will restate the basis of competition for a myriad of products across multiple major industries,” said Pressure BioSciences president and CEO Richard T. Schumacher in the press release. “We have assembled a strong and differentiated IP position and unique engineering and scientific expertise to unleash this opportunity, for PBI and for clients worldwide. We made the critical decision in early 2022 to pivot our business focus and resources almost entirely onto accelerating the UltraShear platform, building commercial-stage UST processing equipment, creating pivotal technology demonstrations with select partners in multiple industries, and accelerating our path to commercial traction and a revenue growth inflection. . . . Astonishing early demonstrations of UltraShear’s unique differentiation of products continue to mount up, and more partners and early marketing results are gathering already for revenue acceleration in Q1 and throughout all of 2023. We are grateful daily for the patient support of our many long-term investors, and we are excited to have them at our side as PBI enters an exciting new era of revenue growth, profitability, and a planned uplist to a national exchange in 2023.”

To view the full press release, visit

About Pressure BioSciences Inc.

Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. PBIO’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented-enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control biomolecular interactions (e.g., cell lysis, biomolecule extraction). The company’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of PBIO’s pressure-based technologies in the following areas: (1) the use of its recently acquired, patented technology from BaroFold Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of its recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room-temperature, stable, low-acid liquid foods that cannot be effectively preserved using existing nonthermal technologies. For more information, visit the company website at

NOTE TO INVESTORS: The latest news and updates relating to SYATF are available in the company’s newsroom at

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Recent NewsBreaks

NewsBreaks Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).